CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 152 enrolled
Drug / intervention
adalimumabbiological
Likely dose
adalimumab 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00566722
NCT00566722Phase 3Completed
CompareCT.gov

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Abbott·interventional·Posted Dec 4, 2007·Updated Apr 12, 2011

In Brief

A Phase 3 clinical trial evaluating adalimumab for Psoriasis. Completed, enrolled 152 participants across 25 sites in 2 countries.

Detailed Summary

The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2007
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.6 years ago

Interventions

adalimumabbiological

Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.